{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:13:45Z","timestamp":1792289625913,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.yebeh.2017.08.039","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T13:17:41Z","timestamp":1505827061000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":384,"special_numbering":"C","title":["Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy"],"prefix":"10.1016","volume":"76","author":[{"given":"Baibing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunmi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austen","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Legge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Detyniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.08.039_bb0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/14740338.2011.588597","article-title":"Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications","volume":"10","author":"Hamed","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","article-title":"Side-effects of antiepileptic drugs: the economic burden","volume":"23","author":"de Kinderen","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0030","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.yebeh.2004.06.013","article-title":"Effects of antiepileptic medications on psychiatric and behavioral comorbidities in children and adolescents with epilepsy","volume":"5 Suppl 3","author":"Glauser","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0035","first-page":"138","article-title":"Behavioral and cognitive effects of anti-epileptic drugs","volume":"9","author":"Cavanna","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0040","first-page":"S53","article-title":"Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0045","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/j.1528-1157.1999.tb00887.x","article-title":"Psychiatric syndromes related to antiepileptic drugs","volume":"40 Suppl 10","author":"Schmitz","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40261-013-0070-4","article-title":"Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials","volume":"33","author":"Biton","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/seiz.2000.0405","article-title":"Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables","volume":"9","author":"Trimble","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0070","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1517\/14740338.6.3.241","article-title":"The safety of levetiracetam","volume":"6","author":"Sirsi","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1528-1157.1997.tb01128.x","article-title":"Quality of life of people with epilepsy: a European study","volume":"38","author":"Baker","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.05.021","article-title":"Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy","volume":"18","author":"Park","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1046\/j.1528-1157.2002.40001.x","article-title":"Risk factors for suicide in epilepsy: a case control study","volume":"43","author":"Nilsson","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5698\/1535-7511-11.3.90","article-title":"Anxiety disorders in epilepsy: the forgotten psychiatric comorbidity","volume":"11","author":"Kanner","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.70.2.186","article-title":"Fear as the main feature of epileptic seizures","volume":"70","author":"Biraben","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yebeh.2010.06.024","article-title":"Postictal affective episodes","volume":"19","author":"Kanner","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1528-1167.1990.tb06305.x","article-title":"Acute postictal psychosis: a stereo EEG study","volume":"31","author":"So","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.1996.00550030070024","article-title":"Postictal psychiatric events during prolonged video-electroencephalographic monitoring studies","volume":"53","author":"Kanner","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1528-1157.1999.tb01996.x","article-title":"Violence and epilepsy: a close relation between violence and postictal psychosis","volume":"40","author":"Kanemoto","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005053-198608000-00005","article-title":"Mood change preceding epileptic seizures","volume":"174","author":"Blanchet","year":"1986","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0130","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/j.1528-1167.2008.01680.x","article-title":"Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities","volume":"49","author":"Caplan","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2013.0599","article-title":"The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre","volume":"15","author":"Kang","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrneurol.2012.184","article-title":"Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling","volume":"8","author":"Wood","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0150","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1212\/WNL.0b013e3181eccfb5","article-title":"Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case\u2013control study","volume":"75","author":"White","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0160","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/JCP.0b013e318253a186","article-title":"Behavioral adverse effects of antiepileptic drugs in epilepsy","volume":"32","author":"Eddy","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1059-1311(97)80066-0","article-title":"A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities","volume":"6","author":"Bhaumik","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0170","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0175","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.yebeh.2005.07.012","article-title":"Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation","volume":"7","author":"Tzitiridou","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40263-013-0063-0","article-title":"The long-term safety of antiepileptic drugs","volume":"27","author":"Gaitatzis","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0185","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/WNL.56.9.1177","article-title":"Differential cognitive and behavioral effects of carbamazepine and lamotrigine","volume":"56","author":"Meador","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.yebeh.2009.12.026","article-title":"Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age","volume":"17","author":"Saetre","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2016.10.020","article-title":"A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment","volume":"66","author":"Huber","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yebeh.2016.05.007","article-title":"Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study","volume":"61","author":"Singh","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yebeh.2016.06.005","article-title":"Adjunctive perampanel in refractory epilepsy: experience at tertiary epilepsy care center in Tours","volume":"61","author":"Maurousset","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0220","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1528-1167.2006.00973.x","article-title":"Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam","volume":"48","author":"Carunchio","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.08.039_bb0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017305462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017305462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T22:44:09Z","timestamp":1602974649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017305462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":44,"alternative-id":["S1525505017305462"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.08.039","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}